# 18F ML-10 for Early Detection of Response of Brain Metastases to SRS

> **NCT00696943** · PHASE2 · TERMINATED · sponsor: **Aposense Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Metastasis to Brain of Unknown Primary

## Interventions

- **DRUG:** ([18F]-ML-10)

## Key facts

- **NCT ID:** NCT00696943
- **Lead sponsor:** Aposense Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Replaced by a global study protocol NST-CA004
- **Last updated:** 2013-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00696943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00696943, "18F ML-10 for Early Detection of Response of Brain Metastases to SRS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00696943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*